Overview

Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This trial will investigate the pharmacokinetics, safety and tolerability of BI 695501 and to establish pharmacokinetic equivalence of BI 695501 to adalimumab.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Adalimumab